Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA)

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions
Cardiac Arrest
Interventions
DRUG

inhaled nitric oxide (iNO)

In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.

DRUG

Sham

In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.

Trial Locations (4)

M5B1W8

NOT_YET_RECRUITING

St. Michael's Hospital, Toronto

M5G2C4

RECRUITING

Toronto General Hospital, Toronto

M5T2S8

NOT_YET_RECRUITING

Toronto Western Hospital, Toronto

Unknown

RECRUITING

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

lead

The Hospital for Sick Children

OTHER